helpline 01494 601 400

TSC

GW Pharmaceuticals begins phase 3 Epidiolex study in tuberous sclerosis complex

GW Pharmaceuticals has announced the start of a Phase 3 clinical trial of Epidiolex® (a cannabidiol-based medication) as an adjunctive therapy for the treatment of epileptic seizures in the rare genetic disorder tuberous sclerosis complex (TSC).

Subscribe to RSS - TSC